NRXP
NRX Pharmaceuticals Inc.
$3.10
+$0.08(+2.65%)
35
Overall
40
Value
30
Tech
--
Quality
Market Cap
$59.12M
Volume
1.11M
52W Range
$1.12 - $6.01
Target Price
$36.25
Order:
Income Statement
| Metric | Trend | Chart | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|
| OPERATING EXPENSES | |||||||
| Operating Expenses | $51.4M | $115.8M | $44.3M | $27.8M | $18.5M | ||
| Research & Development | $10.6M | $20.3M | $17.0M | $13.4M | $6.2M | ||
| Research Expense | $10.6M | $20.3M | $17.0M | $13.4M | $6.2M | ||
| Selling, General & Administrative | $11.4M | $74.9M | $27.3M | $14.2M | $13.5M | ||
| General & Administrative Expenses | $11.4M | $74.9M | $27.3M | $14.2M | $13.5M | ||
| Salaries & Wages | -- | -- | -- | $387.0K | $486.0K | ||
| Depreciation & Amortization | -- | -- | -- | -- | $849.0K | ||
| Depreciation & Amortization | -- | -- | -- | -- | $849.0K | ||
| Amortization | -- | -- | -- | -- | $849.0K | ||
| Other Operating Expenses | $-29.3M | $-20.6M | -- | -- | -- | ||
| OPERATING INCOME | |||||||
| Operating income | $-51.4M | $-115.8M | $-44.3M | $-27.8M | $-18.5M | ||
| EBITDA | $-51.7M | $-93.0M | $-39.8M | $-34.4M | $-29.8M | ||
| NON-OPERATING ITEMS | |||||||
| Interest Expense (Non-Operating) | $56.0K | $18.0K | -- | $120.0K | -- | ||
| Intinc | -- | -- | $249.0K | $494.0K | $44.0K | ||
| Net Non-Operating Interest Income/Expense | $-56.0K | $-18.0K | $249.0K | $494.0K | $44.0K | ||
| Gain on Sale of Securities | $-27.0K | $1.7M | $255.0K | $20.0K | -- | ||
| Other Income/Expense | $-273.0K | $19.1M | $4.3M | $-11.0K | $1.7M | ||
| Other Special Charges | $300.0K | $-20.8M | $-4.1M | $20.0K | $-1.7M | ||
| SPECIAL ITEMS | |||||||
| Special Income Charges | -- | -- | -- | $-250.0K | $1.2M | ||
| PRE-TAX INCOME | |||||||
| EBIT | $-51.7M | $-93.0M | $-39.8M | $-34.4M | $-29.8M | ||
| Pre-Tax Income | $-51.8M | $-93.1M | $-39.8M | $-27.3M | $-25.1M | ||
| INCOME TAX | |||||||
| Tax Provision | $-11.0M | $-11.7M | $-9.3M | $-4.3M | $-4.7M | ||
| NET INCOME | |||||||
| Net Income | $-51.8M | $-93.1M | $-39.8M | $-30.1M | $-25.1M | ||
| Net Income (Continuing Operations) | $-51.8M | $-93.1M | $-39.8M | $-30.1M | $-25.1M | ||
| Net Income (Discontinued Operations) | $-51.8M | $-93.1M | $-39.8M | $-30.1M | $-25.1M | ||
| Net Income (Common Stockholders) | $-51.8M | $-348.9M | $-39.8M | $-30.2M | $-25.1M | ||
| Normalized Income | -- | -- | -- | -- | $-26.9M | ||
| TOTALS | |||||||
| Total Expenses | $51.4M | $115.8M | $44.3M | $27.8M | $18.5M | ||
| SHARE & EPS DATA | |||||||
| Average Shares Outstanding | $273.6K | $46.9M | $6.6M | $7.6M | $10.6M | ||
| Average Shares Outstanding (Diluted) | $273.6K | $46.9M | $6.6M | $7.6M | $10.6M | ||
| Shares Outstanding | $268.8K | $66.6M | $7.2M | $9.6M | $16.9M | ||
| Basic EPS | $-1.6 | $-9.42 | $-12 | $-4 | $-2.36 | ||
| Basic EPS (Continuing Operations) | $-1.6 | $-9.42 | $-12 | $-4 | $-2.36 | ||
| Diluted EPS | $-1.6 | $-9.42 | $-12 | $-4 | $-2.36 | ||
| Diluted EPS (Continuing Operations) | -- | $-9.42 | $-12 | -- | -- | ||
| OTHER METRICS | |||||||
| Accrued Preferred Stock Dividends | -- | $255.8M | -- | -- | -- | ||
| Non Recurring Operation Expense | -- | -- | -- | $250.0K | $-1.2M | ||
| Other Gand A | $11.4M | $74.9M | $27.3M | $14.2M | $13.5M | ||
| Other Write Down | -- | -- | -- | $9.0K | -- | ||
| Otherunder Preferred Stock Dividend | -- | $255.8M | -- | -- | -- | ||
| Preferred Stock Dividends | -- | $255.8M | -- | -- | -- | ||
| Rent And Landing Fees | $100.0K | $100.0K | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | NRXP | $3.10 | +2.6% | 1.11M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get NRX Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW